PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsPersonalised cancer vaccines show promise

BioNews

Personalised cancer vaccines show promise

Published 13 April 2015 posted in News and appears in BioNews 797

Author

Dr Nicoletta Charolidi

PET BioNews

A new type of cancer vaccine that enriches the immune system with tailor-made anti-tumour antibodies has shown early signs of promise...

A new type of cancer vaccine that enriches the immune system with tailor-made anti-tumour cells has shown early signs of promise.

The small-scale trial was conducted at the Washington University School of Medicine in St Louis, USA and published in the journal Science. Three patients with advanced melanoma - a type of skin cancer -  received the experimental treatment almost two years ago. Since then, one has been in remission, the second remained stable throughout the treatment and the third showed a temporary improvement.

Melanoma is caused by the sun's ultraviolet radiation damaging the DNA of skin cells, leading to mutations that vary from person to person. Some of these mutations result in small unique proteins, or neoantigens, that end up on the surface of tumour cells. These can be ideal targets for bespoke anti-cancer vaccines.

The researchers sequenced the complete genome of each patient, and they then compared the DNA of the tumour cells with the DNA in that person's healthy tissues. This process helped them identify every possible unique neoantigen for each patient. They narrowed down the search using a computer algorithm to determine the best candidates for developing a vaccine. To increase the chances of success, seven neoantigens were selected for each patient.

The neoantigens were mixed with specialised immune cells, known as dendritic cells, from each patient. When these cells were re-introduced into the patients' blood stream, they instructed their immune T cells to find and attack the tumour cells that bore the selected neoantigens.

Dr Gerald Linette, who led the trial, said: 'Many researchers have hypothesised that it would be possible to use neoantigens to broadly activate the human immune system, but we didn't know that for sure until now.'

A series of blood tests from the patients showed that in each case they had produced a substantial immune response against their individual melanomas. Dr Linette noted: 'Our team is very encouraged by the quality of the immune response directed against the melanoma neoantigens in all three patients. Our results are preliminary, but we think the vaccines have therapeutic potential.'

However, the team acknowledges that it's too early to judge the effectiveness of the treatment. The melanoma participants had received surgery and chemotherapy prior to the tailored vaccination. Further trials with more patients will follow later this year.

Dr Alan Worsley, of Cancer Research UK, said: 'At the moment it's not clear how effective this immunotherapy would be at killing cancer cells in the body and improving survival, but this promising study sets the stage for creating vaccines that are designed to target each patient's individual tumour in the future.'

Personalised vaccines might also be developed against other types of cancer with high mutation rates, including lung, bladder and certain colorectal, breast and ovarian cancers.

Sources and References

  • 02/04/2015
    Science
    A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
  • 02/04/2015
    AAAS (press release)
    Personalized cancer vaccines may fight tumors
  • 03/04/2015
    BBC News
    Personal cancer vaccine research 'exciting' say experts
  • 02/04/2015
    The Guardian
    Personalised cancer vaccines show early signs of promise in trial
  • 02/04/2015
    The Independent
    Scientists begin pioneering cancer vaccine which attacks tumours of individual patients

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
16 January 2023 • 1 minute read

UK to develop personalised cancer vaccines for NHS patients

by Ochuko Oyeye

The UK Government has announced a deal to accelerate research into vaccines for cancer...

Image by Matthew Daniels via the Wellcome Collection. Depicts human cells, showing the stages of cell division.
CC BY 4.0
Image by Matthew Daniels via the Wellcome Collection. Depicts human cells showing the stages of cell division (starting with interphase at the top and progressing anticlockwise, the stages shown are prophase, prometaphase, metaphase, early anaphase, anaphase and telophase).
News
16 January 2023 • 1 minute read

Genome-edited cancer cells destroy brain tumours in mice

by Sarah Pritchard

Cancer cells have been trained using CRISPR-based genome editing to find and eradicate deadly glioblastoma brain tumours in mice...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
19 February 2018 • 2 minutes read

Stem cell vaccine works against multiple cancers in mice

by Dr Charlott Repschläger

Researchers successfully used inactivated induced pluripotent stem cells to elicit an immune response against different cancers in mice...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 July 2017 • 3 minutes read

First personalised vaccines shows promise for skin cancer

by Meetal Solanki

A revolutionary vaccine uses the patient’s own immune response to target tumour cells and could be the first step in bespoke, precision medicine. 

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
12 December 2016 • 2 minutes read

Gene-targeted therapy successful in treating 'undruggable' colon cancer

by Ayala Ochert and 1 others

Researchers have successfully treated a woman with colon cancer using her own immune cells to target a cancer-causing gene that had previously been considered 'undruggable'...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
22 September 2014 • 2 minutes read

'Personalised' skin cancer drug wins NICE approval

by Dr Lanay Griessner

A skin cancer drug designed to be effective in patients whose cancer is driven by a specific gene mutation has been recommended by the National Institute for Health and Care Excellence to treat patients with advanced melanoma...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
22 April 2013 • 2 minutes read

'Gene signature' predicts chemotherapy survival

by Siobhan Chan

Scientists have identified an eight-gene 'signature' that can predict patients' response to chemotherapy...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 November 2012 • 2 minutes read

Gene mutation melanoma drug recommended for NHS use

by Maria Sheppard

A drug which prolongs life in a form of skin cancer associated with a genetic mutation has been recommended for use on the NHS...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
11 June 2012 • 2 minutes read

Pair of gene-targeted melanoma drugs show promise in late-stage clinical trials

by Dr Tamara Hirsch

Two drugs targeting advanced melanoma linked to a mutation in the BRAF gene are more effective than current chemotherapy at slowing the progress of the skin cancer, clinical trial results indicate...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
12 October 2009 • 2 minutes read

Vaccine made from stem cells may help prevent colon cancer

by Dr Will Fletcher

Stem cells could potentially be used to vaccinate people against colon cancer. This surprising conclusion was made by researchers from China and the US after laboratory mice immunised with human embryonic stem (ES) cells experienced a dramatic decline in tumour growth compared to control mice. The idea that embryonic material may generate an anti-tumour response is an old one, but one that has never been tested outside animal research, so to find such an effect wit...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Genetic link to sex crimes found

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels


easyfundraising
amazon

This month in News

  • Popular
  • Recent
20 November 2023 • 3 minutes read

HFEA publishes recommendations for reform of fertility law

13 November 2023 • 2 minutes read

Four BRCA mutation carriers undergo removal of ovaries during C-section 

13 November 2023 • 2 minutes read

Frequent mobile phone use linked to lower sperm count in young men

6 November 2023 • 3 minutes read

Health Council of the Netherlands recommends doubling the 14-day limit on embryo research

30 October 2023 • 2 minutes read

Government to scrap additional IVF screening for same-sex couples

27 November 2023 • 2 minutes read

Research into gene therapy reveals blood cancer risk

27 November 2023 • 2 minutes read

Polish Parliament debates reinstatement of state IVF funding

27 November 2023 • 2 minutes read

Over 100,000 DNA evidence samples must be re-tested in Australia

27 November 2023 • 2 minutes read

Childhood autism associated with infertility in parents

27 November 2023 • 2 minutes read

Unintended consequence of CRISPR/Cas9 genome editing discovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2023 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2023 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856